Axogen, Inc. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Axogen, Inc. is a medical technology company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The Company operates as a single segment, deriving substantially all revenue from U.S. sales of products including Avance, Axoguard, and Avive+.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $61,457 | $48,560 |
| Gross Profit | $46,189 | $34,933 |
| Gross Margin | 75.2% | 71.9% |
| Net Loss | $(19,584) | $(3,834) |
| Diluted EPS | $(0.38) | $(0.08) |
| Operating Cash Flow | $1,565 | $(13,179) |
| Cash & Investments | $101,601 | $41,528 |
| Long-Term Debt | $0 | $48,387 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 26.6% year-over-year, driven by higher unit volume and price changes.
- Debt Extinguishment: The Company fully repaid its Credit Facility in January 2026. This resulted in a one-time loss on extinguishment of debt of $16,849, which significantly impacted the Net Loss for the quarter.
- Equity Financing: In January 2026, the Company completed an underwritten public offering of 4.6 million shares, raising net proceeds of $133,252. Proceeds were used to pay off debt and fund working capital.
- Expense Increases: Total costs and expenses rose 34.0% to $49,021, primarily due to increased compensation costs, stock-based compensation, and marketing programs.
- Liquidity: Cash and investments increased by $60,073 compared to the prior year-end, bolstered by the equity offering.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash, investments, and product sales to fund operations for at least the next twelve months. The strategy focuses on expanding nerve repair indications and deepening presence in high-potential accounts (Level 1 trauma centers).
- Reimbursement: Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement by 40% for hospital outpatient and 35% for ASC-based procedures. The Company also received positive coverage decisions from Cigna and Elevance Health.
- Risks:
- Grant Clawbacks: The Company must maintain specific headcount and payroll thresholds through December 31, 2026, to avoid repaying up to $950 in economic development grants.
- Macroeconomic Factors: Potential trade disputes and economic instability could impact net revenue.
- Concentration: Substantially all revenues are derived from U.S. customers.
Investor Verification Checklist
- Verify the sustainability of the 26.6% revenue growth rate in subsequent quarters.
- Confirm the Company's ability to meet the job creation milestones required to retain the $1,250 in economic development grants.
- Monitor the impact of the new CMS reimbursement codes on actual facility adoption and revenue realization.
- Review the burn rate of the remaining cash proceeds ($63.5 million after debt payoff) against the stated 12-month runway.
- Assess the impact of increased stock-based compensation ($6.8 million in Q1) on future profitability.